Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest announcement is out from Neuren Pharmaceuticals Limited ( (AU:NEU) ).
Neuren Pharmaceuticals, in collaboration with Acadia Pharmaceuticals, has submitted a Marketing Authorization Application for trofinetide to the European Medicines Agency, targeting the treatment of Rett syndrome. If approved, trofinetide will be the first authorized therapy for this condition in the EU, potentially enhancing Neuren’s market presence and financial prospects through milestone payments and royalties.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals is focused on developing drug therapies for serious neurological disorders that emerge in early childhood and have limited treatment options. Recognized for addressing urgent unmet needs, its programs have received orphan drug designation in the U.S., which provides incentives for developing treatments for rare diseases. Neuren has licensed trofinetide, a drug approved in the U.S. and Canada for Rett syndrome, to Acadia Pharmaceuticals for global commercialization.
YTD Price Performance: 2.91%
Average Trading Volume: 1,077
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $958.7M
Learn more about NEU stock on TipRanks’ Stock Analysis page.
